Evidence map›Paper›PMID 10890901›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2000

A role for Src kinase in spontaneous epileptiform activity in the CA3 region of the hippocampus.

P P Sanna, F Berton, M Cammalleri, M K Tallent, G R Siggins, F E Bloom, W Francesconi

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Antiepileptic Therapy ofEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  3. Article
  4. Differential Impact of Severity and Duration ofFrontiers in cellular neuroscience · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Astrocyte control of synaptic NMDA receptors contributes to the progressive development of temporal lobe epilepsy.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Unique domain anchoring of Src to synaptic NMDA receptors via the mitochondrial protein NADH dehydrogenase subunit 2.Proceedings of the National Academy of Sciences of the United States of America · 2004
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

P P SannaDepartment of Neuropharmacology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
F Berton
M Cammalleri
M K Tallent
G R Siggins
F E Bloom
W Francesconi
Scripps Research Institute · US

Funding

SYSTEMIC NEUROPHARMACOLOGYP50AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE · PI KOOB, GEORGE F · 1985 to 2002
$5.1M
SOMATOSTATIN RELATED PEPTIDES AND BRAIN FUNCTIONR01MH044346 · NIMH · SCRIPPS RESEARCH INSTITUTE · PI SIGGINS, GEORGE ROBERT · 1999 to 2003
$1.1M
SOMATOSTATIN AND BRAIN FUNCTIONR37MH044346 · NIMH · SCRIPPS RESEARCH INSTITUTE · PI SIGGINS, GEORGE ROBERT · 1988 to 1997
–
NIAAA NIH HHS P50 AA006420NIAAA NIH HHS P50AA06420NIMH NIH HHS MH44346NIMH NIH HHS R01 MH044346
6 · The paper itself

Abstract

Members of the Src family of nonreceptor protein tyrosine kinases (PTKs) have been implicated in the regulation of cellular excitability and synaptic plasticity. We have investigated the role of these PTKs in in vitro models of epileptiform activity. Spontaneous epileptiform discharges were induced in vitro in the CA3 region of rat hippocampal slices by superfusion with the potassium channel blocker 4-aminopyridine in Mg(2+)-free medium. In hippocampal slices treated in this fashion, Src kinase activity was increased and the frequency of epileptiform discharges could be greatly reduced by inhibitor of the Src family of PTKs, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2), but not by the inactive structural analog 4-amino-7-phenylpyrazol[3,4-d]pyrimidine (PP3). 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine also reduced epileptiform activity induced by either 4-aminopyridine or Mg(2+)-free medium alone. These observations demonstrate a role for Src family PTKs in the pathophysiology of epilepsy and suggest potential therapeutic targets for antiepileptic therapy.

Indexed as

2-Amino-5-phosphonovalerate4-AminopyridineAnimalsElectrophysiologyEnzyme InhibitorsEpilepsyExcitatory Amino Acid AntagonistsHippocampusIn Vitro TechniquesMagnesiumMalePotassium Channel BlockersPyrimidinesRatsRats, WistarReceptors, N-Methyl-D-Aspartate2-Amino-5-phosphonovalerate4-AminopyridineAG 1879Enzyme InhibitorsExcitatory Amino Acid AntagonistsMagnesiumPotassium Channel BlockersPyrimidinesReceptors, N-Methyl-D-Aspartatesrc-Family Kinases

Identifiers

PMID10890901
PMCPMC27003
OpenAlexW2080349922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.